A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, a trial has found.

Almost one in five patients with advanced melanoma survived for five years after receiving the innovative treatment ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

In the 11 years since it was approved for the treatment of melanoma, pembrolizumab (Keytruda) has become the go-to for adjuvant or neoadjuvant therapy for advanced melanoma, despite the potential ...

Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- ...

These studies underscore the power of Veracyte, Inc. (NASDAQ:VCYT)’s whole-transcriptome-based GRID platform, which now ...